Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/vaccine-adjuvants-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Vaccine AdjuvantsVaccine adjuvant patents: mapping who holds the core emulsion and TLR-agonist claims
- Filings peaked in 2019 at 31 and have since flattened, with the 2022 midpoint at 16 — a sign the field is consolidating around established formulations rather than expanding into new chemistry.
- The five most-cited records are all oil-in-water emulsion patents, one from 1999 carrying 1,079 citations — foundational claims that still shape freedom-to-operate analysis today.
- The top 5 assignees hold 46.3% of all 320 records in scope, and the top 10 hold 69.4% — concentrated enough that a new entrant's formulation choices are constrained from the outset.
320
Published Records
46%
Top-5 Share of All Records
-83%
3-Yr Growth (lag-adjusted)
US
Leading Jurisdiction
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview
What the vaccine adjuvant patent record shows
Vaccine adjuvant patenting sits at the intersection of formulation chemistry and immunology: claims cover everything from squalene-based emulsions to TLR agonist conjugates and nanoparticle delivery systems. The dataset behind this page spans 320 published records filed between 2015 and mid-2026, drawn from a search built around immune response magnitude, reactogenicity, dose sparing and manufacturing consistency — the practical concerns that separate a lab formulation from one that can be manufactured at scale.
Filing activity peaked in 2019 and has trended flat to declining since, which is consistent with a field where the dominant emulsion chemistries were established years ago and recent activity concentrates on refinement and combination claims rather than new base chemistries. Because publication typically lags filing by around 18 months, the final one or two years in any trend chart will understate true filing activity.
Filing activity by year, 2017–2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Vaccine Adjuvants covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The data
Filing trends and technology composition
Two views of the same 320-record dataset: how filing volume has moved year over year, and which IPC subclasses the records fall into.
A peak in 2019, then a plateau
Filings rose from 8 in 2017 to a peak of 31 in 2019, then settled near the 2022 midpoint of 16 through to the most recent partial year. That pattern points to a mature core technology rather than one still in an expansion phase — new filers are more likely to be competing for refinements than staking out entirely new ground.
Medicinal preparations dominate, therapeutic activity close behind
Every record in scope carries an A61K medicinal-preparations classification by construction of the search, and 47.5% of the 320 records also carry an A61P therapeutic-activity class. Smaller but notable shares sit in C07D heterocyclic compounds (18.1%), C12N microorganisms and genetic engineering (6.9%), and C07K peptides and proteins (4.7%) — the last two point to biologic and peptide-based adjuvant approaches that remain a minority of filings against the classical small-molecule and emulsion base.
Shares are the percentage of the 320 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Vaccine Adjuvants covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Vaccine Adjuvants with Eureka
This page is one run against one query. Ask Eureka your own question about vaccine adjuvants and every answer comes back with the patent numbers behind it.
Try EurekaKey patents
The claims setting the boundaries
Representative recent filing
Toll-like receptor agonist-nanoparticle vaccine adjuvant
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Compositions and methods are provided relating to TLR agonist nanoparticle vaccine adjuvant formulations.Filed by The Board of Trustees of the Leland Stanford Junior University, published 2024-06-27 as US20240207394A1.
Most-cited records in scope
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO1999011241A1 | Oil in water emulsions containing saponins | 1,079 |
| 2 | WO2001021152A1 | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant | 700 |
| 3 | WO2001021207A2 | Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines | 665 |
| 4 | WO2005097181A1 | Microfluidized oil-in-water emulsions and vaccine compositions | 255 |
| 5 | US20040258701A1 | Microfluidized oil-in-water emulsions and vaccine compositions | 226 |
| 6 | GB2189141A | Immunological adjuvant | 115 |
| 7 | US4806352A | Immunological lipid emulsion adjuvant | 108 |
| 8 | US20050220814A1 | Microfluidized oil-in-water emulsions and vaccine compositions | 103 |
| 9 | WO2002072012A2 | A novel proteosome-liposaccharide vaccine adjuvant | 93 |
| 10 | US20030044425A1 | Novel proteosome-liposaccharide vaccine adjuvant | 76 |
Citation counts favour older records simply because they have had longer to accumulate citations inside this corpus — treat them as a signal of influence on the field, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Vaccine Adjuvants covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers mean for a filing strategy
Four patterns in the data that matter more than the raw counts on their own.
Concentration
46.3% of 320 records
held by top 5 assignees
The core chemistry is locked up early
Nearly half of all records in scope trace back to five assignees. The most-cited patents in the set — the oil-in-water emulsion families dating back to 1999 and 2001 — are foundational enough that most new filings sit downstream of them, refining delivery or combining known adjuvant classes rather than replacing them.
Freedom-to-operate work here should start with the emulsion composition claims, not the newest filings.
Trend
31 filings in 2019
peak year, vs. 1 in the latest partial year
Filing activity has flattened, not grown
The climb from 8 filings in 2017 to a 2019 peak of 31 was followed by a plateau near the 2022 midpoint of 16. A flat trend after a peak usually signals that the accessible claim space around a known chemistry has been substantially filed, pushing new work toward adjacent formulations or delivery mechanisms.
Expect competitive pressure to show up in combination and delivery claims, not in new base adjuvant chemistries.
Geography
US 73 · EPO 57 · Australia 37
top receiving offices
Filing coverage is US- and Europe-led
The United States and the European Patent Office receive the largest share of filings in scope, with Australia, WIPO/PCT, Canada and India following. That ordering suggests most applicants are pursuing US and European protection first, then extending via PCT into secondary markets.
A competitor entering only through India or Canada first is worth flagging as an outlier strategy.
Collaboration
10 co-assignee pairs
strongest pair: 15 shared records
Collaboration is concentrated in a few pairings
Co-assignee filing is not widespread in this dataset — only ten pairs appear at all, and the strongest single pairing accounts for 15 shared records. That points to a small number of institutional partnerships (research institute plus commercial developer) doing most of the joint filing, rather than an open collaborative norm across the field.
Watch these specific pairings for signs of a shared platform moving toward commercialisation.
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to vaccine adjuvants, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Vaccine Adjuvants covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who holds the claim space
The assignee ranking covers 72 companies counted in records — the full set the data endpoint returns, not a top-50 or top-100 cut. The leader holds 36 records; fifth place holds 22; tenth place holds 11 — a steep drop-off after the first handful, then a long tail of single- and low-digit filers.
Leader
36 records
top-ranked assignee
A clear leader, then a fast decline
The top-ranked assignee holds 36 of the 320 records in scope, roughly 60% more than the fifth-place holder at 22. That gap is wide enough to call this a leader-plus-challengers structure rather than an even field.
New entrants should assume the leader's formulation claims are the ones to design around first.
Mid-field
22 to 11 records
fifth to tenth place
A shallow mid-tier before the long tail begins
Positions five through ten span 22 down to 11 records — a much gentler slope than the drop from the leader. This is the group most likely to be actively defending or extending specific formulation niches rather than holding broad platform claims.
Licensing conversations are often more tractable with this group than with the leader.
Momentum
0 in the latest year
across several major assignees tracked
Recent-year activity has gone quiet among established filers
Several of the assignees with the largest historical portfolios show no new filings in the latest tracked year. Given the roughly 18-month publication lag, this likely understates true activity, but it is also consistent with a field where the largest holders have already staked out their core claims.
A quiet incumbent is not necessarily an inactive one — check pending applications separately before assuming white space.
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| 3M Innovative Properties Co. | 0 | — |
| GlaxoSmithKline Biologicals SA | 0 | — |
| Sumitomo Pharma Co., Ltd. | 0 | — |
| Pfizer Products Inc. | 0 | — |
| VAXFORM LLC | 0 | — |
| Zoetis Services LLC | 0 | — |
| Zydus Lifesciences Ltd. | 0 | — |
| National Institute of Infectious Diseases, Japan | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Vaccine Adjuvants covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's next
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, licensing, or identifying open claim space.
Run a freedom-to-operate check against the leader's portfolio
With one assignee holding 36 of 320 records and the top 5 holding 46.3%, any new formulation should be checked against the leading assignees' claims before development proceeds further.
Explore assignee claims in EurekaProbe the under-claimed branches before committing to a formulation
Peptide-based, nanoparticle-delivery and organo-metallic adjuvant approaches carry a small share of the 320 records relative to the emulsion core, which may leave room for a first-mover claim.
Map white space in EurekaTrack the quiet incumbents for pending filings
Several major assignees show zero filings in the latest tracked year, but the roughly 18-month publication lag means recent activity may not yet be visible. Set up monitoring rather than assuming the field has gone static.
Set up portfolio monitoring in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Vaccine Adjuvants covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions on vaccine adjuvant patents
Within this 320-record dataset, one assignee leads with 36 records, well ahead of the fifth-ranked holder at 22. The top 5 assignees together account for 46.3% of all records in scope, and the top 10 account for 69.4%, indicating a field where a handful of companies control most of the filed claim space. The remaining 62 ranked assignees hold progressively smaller counts, forming a long tail typical of a mature but still active filing area.
The most-cited record in this dataset is WO1999011241A1, covering oil-in-water emulsions containing saponins, with 1,079 citations. Several other highly cited records also cover oil-in-water emulsion formulations, including WO2001021152A1 and WO2001021207A2. High citation counts in an older patent reflect its influence on later filings within this corpus rather than current commercial dominance, since older documents have simply had more time to accumulate citations.
Filing activity in this dataset rose from 8 records in 2017 to a peak of 31 in 2019, then flattened, sitting at 16 by the 2022 midpoint. That pattern suggests the field has moved past an initial expansion phase into one focused on refinement of established chemistries. Because publications typically lag filing by about 18 months, the most recent year or two in any such trend understates real activity and should not be read as a definitive decline.
Compared with the dominant A61K and A61P classifications that cover nearly all 320 records, branches like C07K peptide and protein adjuvants (4.7%), C07F organo-metallic compounds (1.3%) and B82Y nanotechnology applications (0.9%) carry a much smaller share of filings. That does not guarantee an easy path to a grant, but it does indicate these sub-areas have fewer competing claims relative to the classical emulsion and small-molecule core, making them worth a closer freedom-to-operate look before assuming they are crowded.
It is moderately concentrated: the top 5 of 72 ranked assignees hold 46.3% of the 320 records in scope, and the top 10 hold 69.4%. That leaves roughly 30% of records spread across more than 60 remaining assignees, each typically holding a small number of filings. For a new entrant, this means the practical competitive set to study closely is small, even though the full list of filers is long.
Answers are grounded in the same dataset. Derived from a Patsnap search on Vaccine Adjuvants covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Vaccine Adjuvants in depth with Eureka
Go past this page: query the whole vaccine adjuvants corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.